Editor's Summaries of the Articles Published in This Issue of Precision Medicine Communications
Clicks: 72
ID: 276387
2022
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
21.3
/100
72 views
29 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #11 of 12 articles by views in Precision Medicine Communications
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
In this issue, Anum and colleagues have reported evidence-based prioritization and scoring of genomic loci interacting with pioglitazone therapeutic response in diabetic patients; Hasan and colleagues designed a study to determine the association of CP2C19*2 loss of function polymorphism with acute coronary syndrome patients receiving Clopidogre, Zaheer, et al., reviewed escitalopram use in depression & the influence of genetic variations on its safety & efficacy, Ahmed and colleagues reviewed and discussed single nucleotide polymorphisms associated with the safety and efficacy of anti-gout medications, while Haroon et al., compiled, reviewed and discussed the studies showing the genetic influence on Losartan's antihypertensive and uricosuric actions.
| Reference Key |
Staff2022precisionEditor's
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Editorial Staff; |
| Journal | Precision Medicine Communications |
| Year | 2022 |
| DOI |
210
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.